Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications-Reference-Cited by-同舟云学术

Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications

Published:2016-08-23 Issue:8 Volume:134 Page:571-573
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Steg Philippe Gabriel¹,Roussel Ronan¹

Affiliation:

1. From French Alliance for Cardiovascular Clinical Trials (FACT), Paris, France (P.G.S.); Université Paris-Diderot, Paris, France (P.G.S., R.R.); INSERM U-1148, LVTS, Paris, France (P.G.S.); DHU FIRE (Fibrosis, Inflammation and Remodelling), Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France (P.G.S., R.R.); National Heart and Lung Institute, ICMS, Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); and INSERM U-1138, Paris, France (R.R.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.116.021914

Reference6 articles.

1. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed July 27 2016.

2. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

3. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

4. Novo Nordisk website. http://www.novonordisk.com/media.html. Accessed May 4 2016.

5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME;British Journal of Diabetes;2020-12-13

2. Series: Cardiovascular outcome trials for diabetes drugs Sitagliptin and TECOS;British Journal of Diabetes;2020-06-05

3. Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018;Endocrinología, Diabetes y Nutrición;2018-12

4. Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update;Endocrinología, Diabetes y Nutrición (English ed.);2018-12

5. Glucagon-like peptide-1 receptor antagonism impairs basal exercise capacity and vascular adaptation to aerobic exercise training in rats;Physiological Reports;2018-07